M&A

British diagnostics developer Mologic announced Monday that it plans to transform from a for-profit company into a social enterprise through an acquisition worth at least $41 million. The Soros Economic Development Fund is leading the takeover with support from the Gates Foundation, according to Mologic’s press release.

Under a new name—Global Access Health—the firm aims to expand affordable access to medical technology in LMICs, including tests for diseases such as bilharzia, Covid-…

Thermo Fisher announced last week that it will buy North Carolina-based clinical research organization PPD for $17.4 billion in cash and approximately $3.5 billion in assumed debt.

In a boost to its pharma services business, the Massachusetts-based company will acquire PPD’s drug development platform, patient recruitment capabilities and laboratory services, the press release said.

The deal is one of several acquisitions for Thermo Fisher this year and, according to STAT, its…

Mentions:

Italian laboratory diagnostics producer DiaSorin announced a deal Sunday to buy Texas-based biological test maker Luminex for $1.8 billion.

The deal—funded through a mix of cash and external financing—will broaden DiaSorin’s presence in the United States and expand its growing diagnostics portfolio with access to Luminex’s “multiplexing technology,” the press release said.

The merger comes just weeks after Roche announced plans to expand its molecular diagnostics portfolio with a…

Sanofi announced on Monday a $476 million investment over five years to build a vaccine production facility in Singapore to strengthen its supply in Asia and “answer more rapidly to future pandemics.”

According to the press release, the site will allow production of “three to four vaccines simultaneously” (versus only one in current industrial sites) and have the “modularity and flexibility” to scale up production for specific vaccines at need. Sanofi did not specify which antigens…

Amgen will acquire California-based immuno-oncology and cancer therapy specialist Five Prime Therapeutics for approximately $1.9 billion, the companies announced last week.

Five Prime’s lead asset—an investigational “Phase 3 ready” antibody targeting gastric and other cancers—fits Amgen’s international expansion strategy: gastric cancer is prevalent in the Asia-Pacific region “where Amgen expects to generate significant volume growth in the coming years,” according to the press release…

Ireland-based rare diseases company Horizon Therapeutics announced Monday that it will buy AstraZeneca spinoff Viela Bio for $3.1 billion—acquiring the Maryland-based biotech’s rare disease medicines portfolio, which includes four drug candidates in nine development programs.

AstraZeneca has agreed to divest its nearly 30% ownership in Viela as part of the acquisition and expects to net up to $780 million once the deal is closed, the British company’s press release said.

Sanofi used the first day of this week’s virtual 39th J. P. Morgan Healthcare Conference (JPM) to announce that it will pay $1.1 billion upfront (and up to $350 million in milestones) to acquire Kymab, giving it full rights to the British biotech’s Phase 2 KY1005 monoclonal antibody, an atopic dermatitis treatment.

Sanofi CEO Paul Hudson, in a JPM presentation, called the acquisition a “perfect fit” for the company’s immunology and inflammation portfolio. The deal is the most…

Mentions:

Merck KGaA announced last week that it is buying German mRNA contract development and manufacturing organization AmpTec, expanding the Darmstadt-based company’s mRNA capabilities in vaccines, treatments and diagnostics for Covid-19 and other diseases.

The Merck KGaA press release said AmpTec’s differentiated polymerase chain reaction (PCR)-based technology has “advantages over other technologies for mRNA manufacturing.” The press release did not disclose financial terms.

The rush by pharma companies to add to an already banner year for mergers and acquisitions continued in recent days.

First, Gilead announced last week that it is buying German chronic hepatitis specialist MYR Pharmaceuticals for almost $1.8 billion in cash and milestone payments.

Next, AstraZeneca said it would scoop up Boston-based immunology company Alexion Pharmaceuticals for $39 billion in cash and equity to build the British-Swedish company’s rare diseases pipeline and…

Pfizer’s Upjohn generics subsidiary and Mylan formally launched Viatris—the new company resulting from their merger—on Monday. With operations in Hyderabad, Pittsburgh and Shanghai, Viatris has projected 2020 revenue of about $19.4 billion, according to FiercePharma.

In the press release announcing its launch, the new company also revealed “a significant global restructuring program” seeking $1 billion in savings.

Mentions: